This study highlights the high real-world incidence of VTE in high-risk ambulatory cancer patients undergoing chemotherapy, emphasizing the potential benefit of targeted thromboprophylaxis.
This large, contemporary, real-world analysis confirmed high rates of VTE in select patients with solid tumors and suggested that the incidence of VTE is high in the real-world setting. Awareness of the benefits of targeted thromboprophylaxis may result in a clinically significant reduction in the burden of VTE in this population.
Khorana et al. (2012) studied this question.